HRT
HRT and Blood Clot (VTE) Risk
How clot risk differs between oral and transdermal HRT — and what that means for your regimen.
Transdermal oestrogen does not increase VTE risk in standard doses. Oral oestrogen slightly does. This is why UK BMS guidance defaults to patches, gels or spray.
Fear of blood clots is one of the most common reasons women avoid HRT — and one of the most preventable. The evidence over the past 15 years has been clarifying, and the modern message is straightforward: it's not HRT that carries the clot risk, it's ORAL oestrogen specifically. Transdermal HRT (patch, gel or spray) does not appreciably increase venous thromboembolism (VTE) risk at standard doses. That distinction matters because most women who are told 'HRT isn't safe for you' because of clot risk are, in fact, entirely suitable for transdermal HRT. Understanding the mechanism, the size of the risks and how modern prescribing routes around them lets you make a decision from evidence rather than fear.
Why route matters so much
- Oral oestrogen is absorbed through the gut and passes through the liver before entering the general circulation ('first-pass effect').
- The liver responds by upregulating production of clotting factors — fibrinogen, factor VII and others — which nudges the coagulation balance towards clot formation.
- Transdermal oestrogen (patch, gel, spray) is absorbed directly into the bloodstream and bypasses the liver entirely.
- Without first-pass hepatic activation, clotting factors are not upregulated, and VTE risk is not measurably raised in large observational studies and meta-analyses.
- The same principle applies to blood pressure, triglycerides and gallbladder disease — all higher with oral, unchanged or minimal with transdermal.
The numbers in plain English
- Baseline VTE risk for a healthy woman in her 50s is around 1–2 per 1,000 per year.
- Oral HRT raises this to roughly 2–3 per 1,000 per year — a doubling of a small risk.
- Transdermal HRT: no detectable increase in VTE risk in the largest analyses (MHRA, ESTHER, EPIC studies, 2019 BMJ meta-analysis).
- For context: pregnancy raises VTE risk to around 10 per 1,000; the combined pill to 5–10 per 1,000; long-haul flights around 5 per 1,000.
- In absolute terms, for most women transdermal HRT adds essentially no additional clot risk on top of daily life.
When transdermal is the clear choice
- BMI over 30 — obesity independently raises VTE risk.
- Age over 60, or over 10 years since menopause.
- Personal history of DVT or pulmonary embolism (specialist-led).
- Family history of VTE in a first-degree relative under 45.
- Known thrombophilia — Factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome.
- Migraine with aura, smoking (though smoking cessation is a bigger win), or reduced mobility.
- Planned long-haul travel — no need to stop HRT, but compression stockings and movement help.
- Any history of stroke or TIA (specialist-led).
Special situations
- Previous provoked clot (e.g. post-surgery, immobility): transdermal HRT usually acceptable after specialist review.
- Previous unprovoked clot or recurrent clots: specialist input essential; often transdermal is still possible with anticoagulation review.
- Planned major surgery: HRT is typically paused 4–6 weeks before major surgery with prolonged immobilisation, then restarted once fully mobile — this is a precaution, not a hard rule.
- Cancer with active anticoagulation: transdermal HRT is often compatible; oncologist and menopause specialist should decide together.
- Progestogen choice matters too — micronised progesterone (Utrogestan) has a neutral clot profile, unlike some older synthetic progestogens.
Everyday things that reduce your clot risk
- Stop smoking — the single biggest modifiable factor.
- Aim for a healthy weight — every kilo helps if BMI is above 30.
- Move regularly — walk breaks every hour if you sit for work.
- Hydrate on flights and long car journeys.
- Wear compression socks for flights over 4 hours if any risk factors apply.
- Stand and walk every 2 hours on long journeys; ankle pumps in your seat between.
- Recognise warning signs and act fast (see below).
Warning signs that need same-day medical assessment
- One-sided calf pain, swelling, warmth or redness — possible DVT.
- Sudden breathlessness, sharp chest pain worse on breathing in, coughing blood — possible pulmonary embolism.
- Sudden weakness, numbness, slurred speech or facial droop — possible stroke; call 999 immediately.
- Severe sudden headache unlike any you've had — possible cerebral event.
- Don't wait, don't self-treat — dial 111 or attend A&E and mention you're on HRT.
Key takeaway
Blood clot risk on HRT is almost entirely about the route. Transdermal HRT — patch, gel or spray — does not measurably raise clot risk, even in women with elevated baseline risk. Oral HRT roughly doubles a small baseline risk. For most women with clot concerns, HRT isn't off the table — it just goes through the skin, not the stomach.
How Dr Awal approaches this in clinic
Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.
- A detailed 60 minute first appointment — no rushed 10-minute slots.
- Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
- Body-identical HRT considered first-line where appropriate.
- Shared-care letters sent to your NHS GP so treatment can continue affordably.
- Follow-up at 3 months to fine-tune your regimen and address side effects.
- Ongoing annual reviews so your plan evolves with you.
Common questions we hear about this
Do I need to be at a certain age to be seen?
No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.
Will my GP continue the prescription?
In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.
What if I've tried HRT before and it didn't suit me?
Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.
How long will I need to stay on treatment?
There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.
Where do you see patients?
All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.
About the author
Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.
Sources & further reading
General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.
Talk it through
Book a private consultation with Dr Awal
Get evidence-based, personalised advice on hrt and blood clot (vte) risk and any related concerns.
Related in HRT
Continue reading
A Comprehensive Guide to HRT
Types of HRT, oestrogen vs progesterone, benefits, side effects — and how to manage them.
Read guide
NHS vs Private HRT in the UK
How NHS and private HRT compare — costs, wait times, choice of preparations and how to transfer prescriptions.
Read guide
HRT Shortages in the UK
Why HRT supply issues happen, current UK availability and safe swaps if your prescription is unavailable.
Read guide